Smoking Cessation Products Market Analysis and Demand with Forecast Overview to 2028

Posted on 2019-07-31 by Mark Hub in Industrial // 0 Comments

According to the latest study published by Fact.MR, the smoking cessation products market witnessed impressive a 12% y-o-y volume growth in 2018 0ver 2017. The study analyzes macro and microeconomic factors that facilitate the recent developments in the smoking cessation products market, to predict future prospects of the market. Ongoing anti-tobacco movements and increasing sales of electronic cigarettes (e-cigarettes) as a smoking cessation product are key drivers for the smoking cessation products market, according to Fact.MR.

For More Details – A sample of this report is available upon request here –

https://www.factmr.com/connectus/sample?flag=S&rep_id=2372

The smoking cessation products market study investigates the key influential factors have procured a rise in the willingness of smokers to quit smoking, which include

The tobacco epidemic is responsible for over 7 million deaths per year worldwide.
Tobacco smoking is the primary cause of a life-threatening disease – Chronic Obstructive Pulmonary Disease (COPD) and it is likely to become the third leading cause of death by 2030.
Growing health & wellness trend is encouraging consumers to adopt healthy lifestyle.
Stringent laws against tobacco smoking in public places are aiding movements against tobacco smoking.
A significant rise in tobacco taxes in most countries is exhorting consumers to quit smoking.

Developed Regions Account for Over 80% Revenue Share in the Smoking Cessation Products Market

Though smoking cessation products are ubiquitous across the globe, the regional markets for smoking cessation products in North America and Europe are the most lucrative markets for stakeholders, according to the Fact.MR study. The study finds that manufacturers in smoking cessation products markets in the U.S. and Europe fathom that tobacco smoking has reached epidemic proportions in these regions, which is reflected in the recent developments in their vital strategies.

Growing demand for smoking cessation products in North America and Europe can be underpinned by the alarming rise in adoption of tobacco products, especially across a young-adult demographic in these regions. According to a survey on Adult Smoking Habits in the UK: 2017, people aged 25 to 34 years had the largest proportion of current smokers in the UK. In the U.S., over 38 million adults smoked cigarettes in 2016 and the largest increase in quitting was among a young-adult demographic in the country, according to the CDC.

Competitive Landscape:

The Fact.MR report on smoking cessation products market enlists leading stakeholders in the market to provide insightful information about recent developments in the winning strategies of leading competitors in the smoking cessation products market. This chapter features comprehensive information, including intensity mapping, key financials, market share analysis, key developments, SWOT analysis, SIC, NACE, & NIACS codes, and global manufacturing facilities, about the each smoking cessation products market player mentioned above. The report provides detailed information about the leading market players including Johnson & Johnson Inc., GlaxoSmithKline plc, Pfizer, Inc, Perrigo Company plc, Cipla Ltd., ITC Limited, Reynolds American Inc., Imperial tobacco ltd., Fertin Pharma, and Alkalon A/S.

Johnson & Johnson Development Corp., a frontrunner in the smoking cessation products market, recently joined Carrot Inc., a digital health company New York Life Ventures and to raise over US$ 25 million to commercialize Pivot™ – smoking cessation program. The company is contributing to the project with its technological expertise in the medical device and pharmaceutical sector to establish stronger position in the smoking cessation products market.

Another frontrunner in the smoking cessation products market, GlaxoSmithKline plc. announced, in collaboration with an American pharmaceutical company – Innoviva, Inc., that the European Commission has authorized expansion of its single inhaler triple therapy – once-daily Trelegy Ellipta. The company is aiming to adopt innovative strategies to offer an inhaler therapy for COPD patients and strengthen its foothold in the smoking cessation products market.

Have Any Query?? Ask Our Industry Expert

https://www.factmr.com/connectus/sample?flag=AE&rep_id=2372

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick